Tandem Diabetes Care Stock (NASDAQ:TNDM)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$17.06

52W Range

$15.75 - $53.69

50D Avg

$24.06

200D Avg

$34.45

Market Cap

$1.13B

Avg Vol (3M)

$1.65M

Beta

1.53

Div Yield

-

TNDM Company Profile


Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2,650

IPO Date

Nov 14, 2013

Website

TNDM Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24
Supplies and Other$475.79M
Pump$434.17M

Fiscal year ends in Dec 24 | Currency in USD

TNDM Financial Summary


Dec 24Dec 23Dec 22
Revenue$940.20M$747.72M$801.22M
Operating Income$-99.13M$-233.23M$-61.81M
Net Income$-96.03M$-222.61M$-94.59M
EBITDA$-99.13M$-194.66M$-72.31M
Basic EPS$-1.47$-3.43$-1.47
Diluted EPS$-1.47$-3.43$-1.47

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q4 24Feb 27, 25 | 4:30 PM
Q3 24Nov 06, 24 | 4:30 PM
Q2 24Aug 02, 24 | 4:30 PM

Peer Comparison


TickerCompany
MDTMedtronic plc
PENPenumbra, Inc.
INSPInspire Medical Systems, Inc.
ABTAbbott Laboratories
NNOXNano-X Imaging Ltd.
PACBPacific Biosciences of California, Inc.
BSXBoston Scientific Corporation
SYKStryker Corporation
PODDInsulet Corporation
ALGNAlign Technology, Inc.
DXCMDexCom, Inc.